Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

NCT04873258 · tracked via the Priya Life Science UK tracker

Sponsor

Richmond Research Institute

Phase

Observational

Started

2019-09-27

Last updated

2026-08-19

Condition(s) studied

HealthyFatty LiverMASLDMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseObesity and Obesity-related Medical Conditions

Investigational drug(s) / intervention(s)

Bioimpedence Vector Analysis

Bioimpedence Vector Analysis: Bioimpedence vector analysis

Study summary

A generic screening study to establish structural and/or functional baselines of specific organs.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Accepted

Inclusion Criteria: 1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent. 2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations. 3. An understanding, ability and willingness to fully comply with project procedures and restrictions. For PART B only: 1\. With a known history of MASLD as evidenced either of: 1. GP diagnosis on HCF 2. Documented Fibroscan or liver US demonstrating MASLD Exclusion Criteria: 1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other) 2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease) 3. Alcohol consumption \>30 units per week 4. An Implanted cardiac devices

Primary outcome measure(s)

Establishment of Classification Tool for Use in Clinical Trials — Study duration (1 year)
The success of the final classification tool (as measured by area under the receiver operator curve (AUROC). The initial measure to generate the dataset will be the presence or absence of MASLD on liver USS.

Trial sites (1)

Facility	City	Region	Status
Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge	London	London	Recruiting

More Richmond Research Institute trials in the UK

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care Recruiting

Serological and PCR Testing for COVID-19 Recruiting

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY Recruiting

Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations Recruiting

Other trials for the same condition

Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants Recruiting

Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes Active, not recruiting

Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet Recruiting

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants Active, not recruiting

A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04873258 on ClinicalTrials.gov ↗ ← All trials in the UK